SGFG
BEAM icon

Silver Grove Financial Group’s Beam Therapeutics BEAM Stock Holding History

Silver Grove Financial Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824 Buy
+24
New +$725 ﹤0.01% 1917

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Silver Grove Financial Group's BEAM Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 24 shares worth $824. The stake represents ﹤0.01% of the portfolio and ranks #1917 among its holdings.

277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Silver Grove Financial Group held 24 shares of Beam Therapeutics worth $824 as of Q2 2026.
  • Beam Therapeutics was a new Silver Grove Financial Group position in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1917 holding.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.